The scale of the problem the guideline addresses is enormous. In the European Union alone, an estimated 22.1 million women and 6.6 million men aged fifty and older were living with osteoporosis in 2019, and 4.3 million new fragility fractures were reported that year. Germany carries a heavy share of this burden: roughly 4.5 million women, or 22.6 percent of the female population, and 1.2 million men are affected, together accounting for about 6.1 percent of the total population. A demographic simulation model projects that fractures attributable to osteoporosis in Germany will climb from 115,000 in 2010 to 274,000 in 2050, accumulating roughly 8.1 million fractures over that period and discounted costs of 88.5 billion euros.

What makes these numbers so troubling is that a proven countermeasure already exists. A substantial body of evidence shows that physical exercise, when properly designed, strengthens the muscular system, improves balance, and reduces the risk of falls and fall-related fractures in older adults, including those with confirmed bone loss. Patients with suspected or confirmed osteoporosis are routinely referred to physiotherapy to tackle fall risk, pain, restricted range of motion, posture, and declining physical function. Yet until recently, German physiotherapists had to work from the interdisciplinary 2023 national osteoporosis guideline, which offers only a few general statements about physiotherapy, or from a 2009 physiotherapy guideline that was never updated.

Building a brand-new guideline from scratch demands years of work, deep expertise, and considerable funding, so the team chose a smarter route: guideline adaptation. This internationally recognized approach takes an existing, high-quality guideline from another country and carefully reshapes it for a new healthcare context. The researchers structured their project around six modules, informed by the ADAPTE Collaboration framework, a methods paper from the German Society for Physiotherapy Science, and established procedures for cross-cultural adaptation of health measures. The study protocol was published prospectively on the Open Science Framework before the work began, and the project received ethical approval in Germany.

The first three modules formed a methodical search-and-select pipeline. Following the PRISMA 2020 reporting standards, the team searched three scientific databases, including MEDLINE, PEDro, and Web of Science, plus nine international guideline databases and relevant professional websites. They screened 873 records in total, 207 from databases and 666 from other methods, applying strict inclusion criteria: the document had to be a comprehensive guideline written specifically for physiotherapists, focused solely on osteoporosis management, published in German or English within the previous five years, and of acceptable methodological quality. Two reviewers screened independently at both the title-abstract and full-text levels, resolving disagreements through discussion.

Two candidates survived the funnel: the 2022 guideline from APTA Geriatrics, the Academy of Geriatric Physical Therapy of the American Physical Therapy Association, authored by Gregory Hartley and colleagues, and the 2022 UK consensus statement on physical activity and exercise for osteoporosis by Brooke-Wavell and colleagues. Both were appraised with the AGREE II instrument, the international gold standard for guideline quality, which rates 23 items across six domains including rigor of development and editorial independence. The American guideline scored 50 percent overall, the UK statement 58 percent, but the APTA Geriatrics document performed better on the two decisive domains, rigor of development and editorial independence, and was selected for adaptation.

Translation came next, and here the team embraced a strikingly modern technique. Rather than relying on a single human translator, they ran the English guideline through two artificial intelligence systems, the Perplexity AI search engine and the neural machine translation service DeepL, producing two independent German versions. Two researchers then synthesized these into a first draft, flagging every word or sentence rated critical or unclear. The draft, along with both AI translations and the original English text, went to a four-member expert committee: two clinical specialists in geriatric physiotherapy and two methodological experts in guideline development, who assessed linguistic accuracy, medical terminology, fit with the German healthcare system, and consistency with the 2023 German interdisciplinary osteoporosis guideline.

A virtual consensus meeting produced a second draft, which then faced its toughest critics: the people who would actually use it. Three practicing physiotherapists, aged 26 to 34 and treating between 2 and 50 osteoporosis patients per month, reviewed the draft for comprehensibility, readability, and feasibility, and gave interviews lasting up to 47 minutes. Two women with osteoporosis, aged 75 and 80, also reviewed the recommendations section. Their feedback drove concrete changes: a definition of impact training was added to a new glossary, the colors distinguishing different exercise types were made more contrasting and red and green were avoided to help visually impaired readers, and the potentially confusing pronoun we was replaced with neutral wording. The patients found the recommendations generally feasible, though some, such as progressive resistance training and jogging, exceeded their personal health restrictions, which the team judged to be individual limitations rather than flaws in the guideline.

Critically, none of the clinical recommendations themselves were altered. The adaptations were contextual: a note pointing German readers to national fall-prevention training recommendations from the Federal Initiative for Fall Prevention, a glossary defining terms such as low-trauma fracture and weight-bearing exercise, color-coded exercise categories, person-first and gender-conscious language, and the omission of the original implementation chapter, which described the American healthcare system and did not transfer. The original guideline’s developers reviewed and approved every change, and the final German version was signed off by the entire research team. It is now available open access on the Open Science Framework, and the team has announced it through national physiotherapy associations, published an accompanying article in a clinical journal, and launched an educational course already delivered in two German physiotherapy clinics with promising evaluations.

The project also reveals an interesting divergence within German-language guidance. A newly published guideline from the osteology umbrella association DVO on physical exercise for fracture prevention clearly recommends high-intensity strength training and impact loading such as jumping and rapid stair climbing where individually feasible, while the adapted APTA Geriatrics guideline is more cautious, emphasizing individual fracture-risk stratification and tailored loading. The two documents contain no fundamental contradiction; they simply emphasize different things, one focusing on what is effective and the other on identifying who should do it and under what safety conditions. Together they give German-speaking physiotherapists a two-pillar evidence base. The authors are candid about limitations, including an unupdated search, a small user-review panel, no formal back-translation, and the source guideline’s own reliance on evidence ending in 2018. Still, the work stands as a template: it shows that careful, participatory adaptation, with AI translation as a starting point rather than a shortcut, can move trustworthy clinical evidence across languages and health systems, and it hands millions of patients with fragile bones a far better chance that the therapy they receive matches the best science available.

Subject of Research: German translation and contextual adaptation of a US clinical practice guideline for physiotherapy management of osteoporosis

Article Title: Physical therapist management of patients with suspected or confirmed osteoporosis – German translation and contextual adaptation of a clinical practice guideline from the Academy of Geriatric Physical Therapy (USA)

Article References: Physical therapist management of patients with suspected or confirmed osteoporosis – German translation and contextual adaptation of a clinical practice guideline from the Academy of Geriatric Physical Therapy (USA). (n.d.). https://doi.org/10.3389/fresc.2026.1933821

Image Credits: AI Generated

DOI: 10.3389/fresc.2026.1933821

Keywords: osteoporosis, physiotherapy, clinical practice guideline, guideline adaptation, fracture prevention, exercise, AGREE II, ADAPTE, machine translation, geriatric rehabilitation, Germany, fall prevention

The research team, led by Miriam T. Y. Leung of Monash University in collaboration with colleagues at the University of Eastern Finland, drew on the FINPARK cohort, a nationwide register-based dataset covering the entire Finnish population. The study included 11,051 people diagnosed with Parkinson’s disease between 2000 and 2009, each matched by age and sex to two comparison individuals without the disease, yielding 22,102 matched controls. By linking records from the Care Register for Healthcare, the Prescription Register, and Statistics Finland through each resident’s unique personal identification number, the researchers could track every dispensing of anti-osteoporosis medication, every hospital admission, and every death across an extraordinary fifteen-year window: five years before the Parkinson’s diagnosis and ten years after it.

The medications under scrutiny were the standard pharmacological arsenal against osteoporosis: bisphosphonates, the workhorse antiresorptive drugs that slow bone breakdown; denosumab, a monoclonal antibody that blocks the cells responsible for bone resorption; and calcitonin, an older hormone-based therapy that has largely fallen out of favor and was withdrawn from the Finnish market in 2012 due to limited efficacy. Annual prevalence was calculated as the proportion of cohort members who received at least one dispensing of any of these drugs in a given year, restricted to people who spent at least sixty days living in the community to allow realistic opportunity for pharmacy dispensing.

The first major finding was unexpected. Contrary to earlier reports suggesting that osteoporosis is chronically under-recognized in people with Parkinson’s, the Finnish data showed that medication use was actually higher among people with the disease than among matched controls. The divergence emerged surprisingly early, three full years before the formal diagnosis of Parkinson’s, when 3.62 percent of people who would later be diagnosed were receiving anti-osteoporosis therapy compared with 2.91 percent of controls. That gap widened dramatically after diagnosis, peaking four years in, when 8.67 percent of the Parkinson’s group were being treated versus just 4.73 percent of the comparison group, and it remained elevated through the end of follow-up.

Why would bone-protecting drugs appear in the records of people three years before anyone has diagnosed their Parkinson’s? The authors point to the prodromal phase of the disease, the period when early motor and non-motor symptoms, including subtle balance problems and increased fall risk, begin to manifest before the classic diagnostic criteria are met. Their own previous work in the same cohort showed that hip fracture risk is already elevated in the years preceding diagnosis. Fractures themselves may also act as a trigger: a person who breaks a bone is more likely to be screened for osteoporosis and started on treatment, and the heightened dispensing observed after hip fractures in this study supports exactly that pathway. Reduced mobility and greater use of psychotropic medications, both documented in this cohort years before diagnosis, further compound the fracture risk.

The second key finding concerns what happens after a hip fracture, the moment when secondary prevention matters most. Among the 1,475 people with Parkinson’s and 1,371 controls who suffered an incident hip fracture during follow-up, treatment patterns were strikingly similar between the two groups. Anti-osteoporosis dispensing peaked within the first year after the fracture, reaching 20.3 percent in the Parkinson’s group and 21.0 percent in the controls, roughly one in five patients. By five years after the fracture, prevalence had settled to around 14 to 16 percent in both groups. In other words, having Parkinson’s neither helped nor hindered access to post-fracture pharmacological prevention, a result that directly contradicts the under-treatment narrative from smaller earlier studies.

Yet the absolute numbers tell a more sobering story. A one-in-five treatment rate after a fragility fracture leaves four in five patients without the therapy that could prevent the next break, and the Finnish figures, while comparable to other Nordic countries, fall far short of the more than 50 percent post-fracture treatment prevalence reported in the United Kingdom. The authors attribute part of this gap to national guideline differences. The Finnish Current Care Guideline on hip fracture recommends anti-osteoporosis medications only for patients expected to regain independent mobility, explicitly excluding those anticipated to remain bedbound, and it places heavy emphasis on fall-risk management, noting that ninety percent of hip fractures result from a fall. Multidisciplinary fracture liaison services, which systematically assess every fracture patient, have been shown elsewhere to raise both treatment rates and fall-prevention efforts, and the study suggests they could play a valuable role in Finland.

Sex differences added another layer of complexity. Women, whether with or without Parkinson’s, received anti-osteoporosis medications at consistently higher rates than men throughout follow-up, reflecting the earlier onset of postmenopausal bone loss. Among women with Parkinson’s, treatment prevalence peaked at 15.5 percent four years after diagnosis, then declined, a pattern consistent with postmenopausal osteoporosis being treated early and later paused. Men with Parkinson’s showed the opposite trajectory, with use climbing slowly to a peak of just 3.16 percent eight years after diagnosis. After hip fracture, women again led with 25.6 percent treated within a year versus 12.2 percent of men, but men’s post-fracture treatment remained elevated for up to five years while women’s declined. The gradual decline in bisphosphonate use beyond four years after diagnosis may reflect not only poor adherence, a well-documented problem with oral bisphosphonates, but also deliberate clinical decisions: guidelines recommend a drug holiday of one to two years after three to five years of bisphosphonate therapy in lower-risk patients to minimize long-term adverse effects.

The study’s strengths lie in its scale and completeness. Nationwide registers minimize selection bias, the fifteen-year follow-up captures the full arc from prodrome to late disease, and the prediagnostic window, never examined before in this context, proved scientifically critical given that fracture risk is already elevated before diagnosis. The limitations are equally instructive: over-the-counter vitamin D and calcium, dispensed without prescription, were invisible to the database; no bone mineral density measurements or blood tests were available to judge whether treatment matched individual bone health; and medications administered intravenously in hospitals, such as zoledronic acid, could not be captured. These gaps mean the true extent of bone-protective care may be somewhat higher than the dispensing records suggest.

The takeaway for clinicians and researchers is that the problem in Parkinson’s may not be unequal access to osteoporosis drugs, but rather that drugs alone are not enough to counteract a risk that is doubled at its source. With sustained fracture risk extending a full decade after diagnosis, the authors argue that additional preventive measures, above all regular and systematic review of fall risk, must run alongside pharmacotherapy. As Parkinson’s prevalence continues its steep global climb, protecting the skeletons of the people it affects may demand a shift from reactive treatment after the break to proactive, multidisciplinary prevention before the fall ever happens.

Subject of Research: Anti-osteoporosis medication use in persons with and without Parkinson's disease in Finland

Article Title: Anti-osteoporosis medications in persons with and without Parkinson disease in Finland

Article References: Leung, M. T. Y., Lamidi, M.-L., Tiihonen, M., Hartikainen, S., Bell, J. S., Turner, J. P., & Tolppanen, A.-M. (2026). Anti-osteoporosis medications in persons with and without Parkinson disease in Finland. Archives of Osteoporosis, 21(1), Article 143. https://doi.org/10.1007/s11657-026-01780-z

Image Credits: AI Generated

DOI: 10.1007/s11657-026-01780-z

Keywords: Parkinson's disease, osteoporosis, hip fracture, bisphosphonates, denosumab, anti-osteoporosis medications, Finland, nationwide cohort, fracture prevention, fall risk, secondary prevention, bone health

The team, led by Marco Antonio Araújo da Rocha-Loures of the Clínica de Reumatismo in Maringá, Brazil, and supported by the Brazilian Society of Rheumatology, conducted an exhaustive search across eight major databases, including PubMed, EMBASE, Scopus, the Cochrane Library, Web of Science, SciELO, PEDro and LILACS, supplemented by gray literature sources. Their aim was to answer a deceptively simple question: in men with primary or secondary osteoporosis, which interventions actually reduce fracture risk and improve bone mineral density? The investigators followed the PRISMA reporting framework and used the Cochrane Handbook for systematic reviews, version 6.5, as their methodological backbone. Statistical analyses were performed in RStudio version 4.3.3, and the risk of bias in each included trial was assessed with the Cochrane RoB 2 tool, the current standard for evaluating randomized studies.

After screening the literature, the reviewers settled on twelve randomized controlled trials. Ten of these tested pharmacological interventions, one examined a nutritional supplement, and one evaluated an exercise program. The pooled study populations had a mean age of 60.9 years, with a standard deviation of 5.2 years, and baseline disease severity that qualifies as established osteoporosis by any conventional definition: average T-scores of minus 2.9 at the lumbar spine and minus 2.7 at the femoral neck. A T-score expresses how many standard deviations a person’s bone density lies below the young adult mean, and values below minus 2.5 define osteoporosis under World Health Organization criteria. These were not marginal cases; these were men with substantially compromised skeletons.

The pharmacological findings centered on two drug classes that dominate osteoporosis therapy worldwide. Bisphosphonates—represented in the included trials by alendronate and risedronate—work by binding to bone mineral and poisoning the osteoclasts, the cells that resorb bone, thereby tipping the delicate balance of bone remodeling toward formation. The antiresorptive effect is well documented, and the trials reviewed here confirmed that both agents produce measurable gains in bone mineral density at the spine and hip in men. Teriparatide, the second major therapy evaluated, takes the opposite mechanistic approach. As a recombinant fragment of human parathyroid hormone, comprising the first 34 amino acids, it is administered by daily injection and acts as an anabolic agent, stimulating osteoblasts to build new bone rather than simply slowing its loss. The landmark trial by Orwoll and colleagues, included in this review, demonstrated significant bone density gains in osteoporotic men treated with teriparatide, and a combination study testing risedronate alongside teriparatide explored whether pairing an anabolic with an antiresorptive agent yields additive benefits.

Yet when the reviewers looked beyond bone density to the outcome that ultimately matters—fractures—the picture became decidedly less reassuring. The effects of pharmacological treatment on fracture risk were described as inconsistent across the included trials. This is not because the drugs have been proven ineffective at preventing fractures; it is because the trials in men were generally too small, too short, or too sparsely powered to detect fracture reduction with statistical confidence. Fractures are relatively rare events even in osteoporotic populations over the time frames typical of clinical trials, and demonstrating a meaningful reduction requires thousands of patient-years of follow-up. Almost all of the definitive fracture data for bisphosphonates and teriparatide come from trials conducted predominantly in postmenopausal women, and regulators and guideline writers have long extrapolated those results to men. The new review makes clear how much of the male-specific evidence base rests on that extrapolation rather than on direct demonstration.

The non-pharmacological arm of the review offered some of its most intriguing, if preliminary, findings. A single exercise-based trial examined resistance training in men with secondary osteoporosis following hemiplegia, using weight-training sessions lasting 60 to 90 minutes per day. That regimen was associated with improvements in bone mineral density, consistent with the mechanistic understanding that mechanical loading stimulates osteogenesis through skeletal strain detected by osteocytes, which in turn signal osteoblast recruitment. The Wolff’s law principle—that bone adapts to the loads placed upon it—has underpinned exercise recommendations for skeletal health for over a century, but robust randomized evidence in older men with established osteoporosis has been scarce. The second non-pharmacological trial tested L-carnitine, a compound involved in mitochondrial fatty acid transport that has been hypothesized to influence bone metabolism through effects on osteoblast activity, and reported bone density benefits as well. Both findings, the reviewers caution, are limited by methodological constraints in the underlying studies, and neither can be considered practice-changing on its own.

Risk of bias across the twelve trials varied considerably, a finding that colors every conclusion the review can offer. The RoB 2 assessment examines domains including the randomization process, deviations from intended interventions, missing outcome data, measurement of outcomes, and selective reporting. Trials of older drugs conducted decades ago often fall short of contemporary standards for blinding, allocation concealment, and pre-registered outcome definitions. When the reviewers weighted the totality of evidence, they concluded that pharmacological therapies do improve bone mineral density in older men, but that the evidence remains insufficient to demonstrate consistent fracture risk reduction, and that non-pharmacological interventions show potential benefits supported only by limited evidence.

The clinical implications of these gaps are considerable. Osteoporosis in men is widely acknowledged to be underdiagnosed and undertreated, and the consequences of that neglect are severe: men account for a substantial fraction of hip fractures, and men who sustain a hip fracture experience higher mortality than women with comparable injuries. Vertebral fractures in men frequently go unrecognized, and secondary causes—including hypogonadism, glucocorticoid use, alcohol excess, and malabsorption—are common yet often uninvestigated. Guidelines from bodies such as the Endocrine Society have recommended bisphosphonates as first-line therapy for men at high fracture risk, but those recommendations rest in large part on bone density surrogates and on fracture data imported from female populations. Surrogate endpoints like bone mineral density correlate with fracture risk, but the correlation is imperfect, and treatments can produce density gains without proportional fracture reduction, as has been demonstrated in other therapeutic contexts.

What the review ultimately argues for is a new generation of adequately powered randomized trials in men, designed with fractures as the primary endpoint rather than bone density. Such trials are expensive and logistically demanding, requiring large sample sizes and multi-year follow-up, but the reviewers contend that they are the only way to place male osteoporosis management on the same evidentiary footing as postmenopausal osteoporosis. They also call for better-designed studies of non-pharmacological approaches, noting that exercise interventions in particular could offer fractal benefits—improved balance, muscle strength, and fall prevention—that drugs cannot provide, and that falls are the proximate cause of the majority of fragility fractures in older adults. An intervention that reduces falls while modestly increasing bone density could, in principle, deliver a combined fracture-prevention effect larger than either mechanism alone.

For the millions of older men living with low bone mass worldwide, the practical takeaways from the review are nonetheless reasonably clear. The existing pharmacological arsenal—bisphosphonates and teriparatide foremost among them—does increase bone density in men, and no signal of unexpected harm emerged from the analyzed trials, making continued use consistent with current guidelines a defensible clinical stance. At the same time, men and their physicians should not assume that the fracture-prevention benefits observed in women have been proven directly in men, and the review’s authors hope their work will spur both researchers and funders to close a gap that has persisted for decades. Bone health in aging men, long a footnote in osteoporosis research, is finally receiving the systematic scrutiny it has long deserved—and the scrutiny reveals just how much work remains to be done.